Hadassah

Conquering Brain Tumors at the Molecular Level

Monday, Dec 9 2013

For Regina Golan-Gerstl, a postdoctoral fellow at the Hadassah-Hebrew University School of Medicine, the fight against brain cancer has been close-up and personal: her mother died of the disease. She has now identified a genetic protein that is directly implicated in the development of the most prevalent brain cancer--glioblastoma.

Initially working in the specialty of pulmonology with Senior Hadassah Prof. Raphael Breuer, researching how cells communicate with one another, Dr. Golan-Gerstl switched to studying brain cancer when her mother became ill.

There is a mechanism called "splicing," she says, where elements of RNA (ribonucleic acid) are cut and recombined like sections of movie film. When a person is sick, Dr. Golan-Gerstl explains, the splicing mechanism doesn't work in the same way. An alternative splicing occurs, thanks to a genetic protein which becomes an activist in the development of cancer. She and her team have found that when the action of this gene is turned off, tumors in mice decrease in size. Dr. Golan-Gerstl adds that their first success has been with brain cancer.

Further investigation is taking place with other metastatic cancers, such as breast cancer. Tackling the problem with colleagues in Hadassah's Neuro-Oncology Department, Dr. Golan-Gerstl relates that they are "working on shutting it down at a molecular level."

Michael Klipper, Chair of Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on the organization's website that "this discovery is comforting for those who are and who have been affected by this horrible disease. For one, it shows them that there are dedicated scientists and researchers who are working around the clock to put an end to this horrible disease. And two, it gives them hope that there actually will one day be a cure for brain cancer."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More